#AI In Oncology Market Size

[marketinsightsenterprises]

AI in Oncology: A Game-Changer in Cancer Care

Artificial intelligence (AI) is revolutionizing oncology, offering innovative solutions that improve cancer diagnosis and treatment. With rising cancer incidence and advancements in AI technology, the global AI in oncology market is poised for significant growth. As AI continues to evolve, its role in transforming cancer care will only grow stronger, offering hope for better outcomes and improved patient experiences. Read more..

[marketreports-blog]

The global AI In oncology for analytical solutions market is valued at USD 947.71 million in 2023 and is projected to reach a value of USD 14,689.67 million by 2032 at a CAGR (Compound Annual Growth Rate) of 35.6% between 2023 and 2032

[market-insider]

AI-Powered Analytical Solutions for Oncology: The Next Step in Cancer Research

The global AI in oncology for analytical solutions market size is expected to reach USD 7.4 billion by 2030. The increasing demand to reduce healthcare costs is expected to be a crucial factor driving the adoption of artificial intelligence (AI) in oncology for analytical solutions. The implementation of artificial intelligence algorithms in oncology can significantly improve the accuracy of procedures and reduce the costs associated with treatment by avoiding unnecessary tests. For instance, a June 2021 study published in Frontiers found that incorporating artificial intelligence in the diagnosis of colorectal cancer helped save around USD 400 million, primarily due to the early detection of cancer.

Gain deeper insights on the market and receive your free copy with TOC now @: AI In Oncology For Analytical Solutions Market Report

The high prevalence of cancer-related diseases worldwide is expected to drive the expansion during the forecast period. For example, the American Cancer Society, Inc. estimates that by the end of 2022, there will be nearly 1.9 million new diagnoses and 609,360 cancer-related deaths in the U.S. Additionally, lung, breast, rectal, and colon cancers were the most common cancers in February 2022, according to the World Health Organization. Moreover, a third of global cancer deaths are attributed to high body mass index, tobacco use, and lack of physical activity. Therefore, the increasing prevalence of this disease globally is expected to increase the adoption of artificial intelligence for more accurate diagnosis, contributing to the growth of the AI in oncology analytical solutions market.

The market is anticipated to grow due to improvements in healthcare infrastructure and the increasing prevalence of cancer. By utilizing artificial intelligence technology, healthcare providers can diagnose and plan treatment procedures with greater ease. The use of artificial intelligence enables earlier and more accurate detection, reducing treatment costs and enhancing the patient experience through personalized treatment. Additionally, the growth is fueled by initiatives from government and non-government organizations that invest in healthcare R&D. For instance, the Indian government plans to introduce healthcare infrastructure programs worth USD 6.8 billion, according to a recent report from IBEF.

[sanskruti01]

Generative AI in Healthcare Market to Grow at an 35.1% CAGR Till 2032!

The global Generative AI in Healthcare Market worth USD 1.07 billion in 2023 is likely to be USD 21.74 billion by 2032, growing at a 35.1% CAGR between 2023 and 2032.

According to the stats published by World Health Organization (WHO), approximately 1.28 million adults (between 30 and 79 years of age) have hypertension. Of these, as little as 42% of adults are diagnosed and treated correctly and the remaining population is unaware of this condition. The majority of this population resides in low to middle-income countries of the world. Despite this substantial number of untreated cases, the rising awareness among doctors and the general population regarding health illnesses associated with hypertension is expected to drive the demand for the required devices.

Download White Paper@ https://www.towardshealthcare.com/personalized-scope/5069

A recent report provides crucial insights along with application based and forecast information in the Global Generative AI in Healthcare Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this Market. This study also provides a detailed overview of the opportunities along with the current trends observed in the Generative AI in Healthcare Market.

A quantitative analysis of the industry is compiled for a period of 10 years in order to assist players to grow in the Market. Insights on specific revenue figures generated are also given in the report, along with projected revenue at the end of the forecast period.

Report Objectives

To define, describe, and forecast the global Generative AI in Healthcare Market based on product, and region

To provide detailed information regarding the major factors influencing the growth of the Market (drivers, opportunities, and industry-specific challenges)

To strategically analyze microMarkets1 with respect to individual growth trends, future prospects, and contributions to the total Market

To analyze opportunities in the Market for stakeholders and provide details of the competitive landscape for Market leaders

To forecast the size of Market segments with respect to four main regions—North America, Europe, Asia Pacific and the Rest of the World (RoW)2

To strategically profile key players and comprehensively analyze their product portfolios, Market shares, and core competencies3

To track and analyze competitive developments such as acquisitions, expansions, new product launches, and partnerships in the Generative AI in Healthcare Market

Companies and Manufacturers Covered

The study covers key players operating in the Market along with prime schemes and strategies implemented by each player to hold high positions in the industry. Such a tough vendor landscape provides a competitive outlook of the industry, consequently existing as a key insight. These insights were thoroughly analysed and prime business strategies and products that offer high revenue generation capacities were identified. Key players of the global Generative AI in Healthcare Market are included as given below:

Generative AI in Healthcare Market Key Players:

Syntegra

NioyaTech

Saxon

IBM Watson

Microsoft Corporation

Google LLC

Tencent Holdings Ltd.

Neuralink Corporation

OpenAI

Oracle

Market Segments :

By Application

Clinical

Cardiovascular

Dermatology

Infectious Disease

Oncology

Others

System

Disease Diagnosis

Telemedicine

Electronic Health Records

Drug Interaction

By Function

AI-Assisted Robotic Surgery

Virtual Nursing Assistants

Aid Clinical Judgment/Diagnosis

Workflow & Administrative Tasks

Image Analysis

By End User

Hospitals & Clinics

Clinical Research

Healthcare Organizations

Diagnostic Centers

Others

By Geography

North America

Europe

Asia-Pacific

Latin America

Middle East and Africa

Contact US -

Towards Healthcare

Web: https://www.towardshealthcare.com/

You can place an order or ask any questions, please feel free to contact at 

Email:  sales@towardshealthcare.com

About Us

We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

[insightfulblogz]

Veterinary Imaging Market Revenue, Segments, Analysis and Forecasts 2032

Veterinary imaging is a critical component in the diagnosis and management of diseases in animals. These imaging techniques allow veterinarians to examine the internal structures of animals, identify diseases, and guide treatment plans without invasive procedures. Veterinary imaging encompasses a wide range of modalities, including X-ray, ultrasound, CT (computed tomography), MRI (magnetic resonance imaging), and endoscopy, each providing unique insights into an animal’s health. The growing importance of veterinary imaging stems from its ability to diagnose conditions early, reduce the need for exploratory surgeries, and improve the accuracy of diagnoses.

Recent advancements in veterinary imaging technology have significantly enhanced diagnostic accuracy and efficiency. For example, the development of portable ultrasound machines has made imaging more accessible in rural and emergency settings. Additionally, innovations in digital radiography and the integration of artificial intelligence in imaging analysis are enabling faster and more precise diagnosis. As pet ownership continues to rise globally, the demand for advanced veterinary imaging equipment is growing, particularly in specialized fields like cardiology, oncology, and orthopedics. Veterinary imaging not only aids in the treatment of companion animals but is also used in livestock and wildlife medicine to improve animal health and welfare.

The Veterinary Imaging Market size was USD 1.85 Billion in 2023 and is expected to Reach USD 3.35 Billion by 2032 and grow at a CAGR of 6.85% over the forecast period of 2024-2032.

Future Growth

Growing awareness of animal health and increased pet ownership will drive demand for veterinary imaging services.

Advancements in AI and machine learning will enhance the accuracy and efficiency of diagnostic imaging in veterinary medicine.

The development of more affordable and portable imaging technologies will make advanced diagnostics more accessible to a broader range of veterinary practices.

The use of 3D imaging and molecular imaging techniques is expected to revolutionize the diagnosis of complex conditions, such as cancer and neurological disorders.

Veterinary imaging will continue to expand its applications beyond companion animals to include livestock and wildlife health monitoring.

Emerging Trends

Artificial intelligence (AI) is increasingly being integrated into veterinary imaging systems to improve diagnostic capabilities. AI algorithms can help detect anomalies in images that might be missed by human radiologists, enabling earlier detection of conditions like tumors or fractures. Additionally, the use of portable imaging devices, such as handheld ultrasound and digital X-ray units, is becoming more prevalent, allowing for quicker and more flexible imaging in emergency or remote settings. Another emerging trend is the use of advanced imaging modalities like MRI and CT, which provide detailed images of soft tissues and are increasingly used for diagnosing complex conditions.

Applications

Veterinary imaging plays a vital role in diagnosing a variety of conditions across different species, including companion animals, livestock, and wildlife. In small animal practices, imaging techniques are commonly used to assess bone fractures, soft tissue injuries, tumors, heart disease, and gastrointestinal disorders. Imaging is also crucial in equine medicine for diagnosing musculoskeletal injuries and in veterinary cardiology for evaluating heart conditions. In livestock management, imaging technologies help monitor herd health, detect infections, and improve breeding programs. Moreover, veterinary imaging is increasingly used in wildlife conservation to track animal health and monitor the effects of diseases in endangered species.

Key Points

Veterinary imaging includes X-ray, ultrasound, CT, MRI, and endoscopy for non-invasive diagnosis.

Advances in AI and portable devices are enhancing diagnostic accuracy and accessibility.

Veterinary imaging is used in a wide range of applications, from companion animals to livestock and wildlife.

Growing pet ownership and demand for advanced diagnostics will drive the market for veterinary imaging.

The integration of 3D imaging and molecular imaging will further expand the capabilities of veterinary diagnostics.

Conclusion

Veterinary imaging has become a cornerstone of modern veterinary care, providing essential diagnostic insights that enhance animal health management. As technology continues to advance, the future of veterinary imaging looks promising, with more accurate, affordable, and accessible diagnostic tools. The increasing integration of AI and mobile imaging solutions will continue to revolutionize the field, ensuring that veterinarians can provide the best possible care for animals across a variety of settings.

Read More Details: https://www.snsinsider.com/reports/veterinary-imaging-market-3226 

Contact Us:

Akash Anand — Head of Business Development & Strategy

Email: info@snsinsider.com

Phone: +1–415–230–0044 (US) | +91–7798602273 (IND) 

[marketsndata]

Global Point-of-Care Diagnostics Market Size, Share, Growth and Forecast 2031

Global point-of-care diagnostics market is projected to witness a CAGR of 7.90% during the forecast period 2024-2031, growing from USD 47.21 billion in 2023 to USD 86.74 billion in 2031.

Factors driving the point-of-care diagnostics market include the rising prevalence of infectious diseases, increased investment in technology that includes artificial intelligence, growing demand for decentralized healthcare solutions, and increased corporate investments. Apart from this, improvement in the trend towards home care improves the patient’s experience and lowers the costs of healthcare as well.

Global point-of-care (POC) diagnostics consists of rapid, on-site tests that enable immediate clinical decision-making. These tests are significant as they allow accurate and timely reporting, improving patient care results and reducing the need for centralized lab facilities. Its high ability to deliver fast, reliable diagnostics at the point of patient care positions it in a valuable category in every healthcare setting, initiating a more efficient, accessible healthcare delivery worldwide.

Companies are strengthening their diagnostics segment through R&D investment to gain a solid stand in the advanced point-of-care diagnostics market. Moreover, they obtain funds to develop their capabilities and speed up innovation in diagnostic solutions. Overall, these strategic initiatives enhance the quality and efficiency of POC diagnostics, fueling market growth and steadily increasing demand for faster, more accurate testing. For instance, in July 2024, NOWDiagnostics, Inc. (NOWDx) closed a USD 22.5 million Series B funding aimed at fast-tracking rapid at-home diagnostic tests. NOWDxwill utilize the funding for the launch of innovative diagnostics, and home-based tests and expand the portfolio of tests. NOWDx has a promising clinical research pipeline of around 30 diagnostic tests, and the company is willing to utilize the funding for the approval and commercialization of these tests.

Similarly, in August 2024, Lumos Diagnostics Holdings Limited (Lumos), a rapid POC diagnostic solutions manufacturer, extended its partnership with the Burnet Institute to conduct a clinical trial of a new POC test for monitoring liver health. This kind of development suggests that the market is expanding and increasing demand to innovate liver function monitoring and pave the way for future home-based tests.  

Technological Advancements of Point-of-Care Diagnostics

Technological advancement is driving the growth of point-of-care diagnostics as a viable means to ease healthcare burdens. These devices are user-friendly and inexpensive, with rapid turnaround times; thus, they suit patients with financial constraints, social stigma, and mobility issues. Miniaturized biochip devices can detect diseases rapidly using simple samples such as blood or saliva. Integrating AI and microfluidic technologies improves diagnostic precision and efficiency, making it possible for POC devices to detect biomarkers in a wide range of conditions, from infectious diseases to oncology and many more. For instance, in June 2023, Sysmex Corporation launched its first point-of-care testing system for Europe, designed to diagnose antimicrobial susceptibility in 30 minutes rapidly. Using microfluidic technology, the system rapidly detects bacteria, analyzes the effectiveness of antimicrobial drugs using urine samples, and is likely to alter conventional approaches toward the diagnosis of infectious diseases and deal with the imperative urgency of speeding up the detection of UTI infections.

Growing Preference for Home Care Driving Market Growth

The growing preference for healthcare services at home is a key driver for growth in the point-of-care diagnostics segment. Patients are now looking for convenient, cost-effective, and more customized care delivery. There has been a rising demand for diagnostic tests that can be performed outside traditional clinical settings. POC diagnostics allow people to track their health conditions from the comfort of their homes. This reduces the number of hospital visits and decreases healthcare costs. The availability, accessibility, and usability of home-based diagnosis solutions are attractive factors contributing to increased usage and driving the market in the health sector. For instance, in March 2023, Cue Health Inc. launched a portfolio of home-based diagnostic test kits that offer company test-to-treat services to help people with easy health management from their homes. The marketed kits include heart health test kits, sexual health test kits, women’s health test kits, metabolic health test kits, and wellness test kits. These kits are enabled with Cue Care, allowing a simple and private collection of samples for the CLIA-certified independent laboratory analysis. The results are efficiently provided in the Cue Health App, coupled with relevant health information.

Favorable Funding Scenario to Fuel Market Growth

The COVID-19 pandemic has significantly transformed the funding landscape of point-of-care diagnostics. Health disparities caused during the pandemic highlight the need for fast, accurate, and accessible testing. In response, funding for R&D has surged to develop advanced and more point-of-care diagnostic tests. That additional funding helped drive faster the development of new POC diagnostics solutions that could rapidly and effectively diagnose and treat health conditions. The capital inflow has also expanded testing capabilities beyond COVID-19 to a broader set of conditions and applications. For this reason, the market is likely to experience tremendous growth, with ongoing investment remaining in a core position to drive diagnostic innovations in terms of improved access to healthcare for populations.

For instance, in March 2024, BioMérieux SA invested USD 10.76 million (NOK 115 million) to develop a small-scale immunoassay POC analyzer with SpinChip Diagnostics ASA. This advanced platform delivers diagnostic performance from a single blood droplet within minutes and has scalability across the POC market. The first product is a high-sensitivity cardiac troponin I test, which will be a monumental step in the method of emergency triaging and treatment of acute heart attacks.

Infectious Disease Testing Products Dominating Point-of-Care Diagnostics Market

Infectious disease testing products hold the largest share of the POC diagnostics market. They create an utmost need to provide rapid, on-site diagnosis for conditions such as COVID-19, HIV, influenza, and tuberculosis. These tests can be done immediately; thus, results can speed up the decisions about treatment, and infectious diseases will not spread faster as they are being diagnosed promptly. The portability and ease with which they may be used in even clinical settings, as well as remote or resource-limited areas, ensure their effectiveness. The growing epidemics of infectious diseases coupled with the technological advancements in POC testing devices further gave strength to these tools for controlling outbreaks and managing public health challenges effectively.

In August 2023, QuidelOrtho Corporation received De Novo FDA approval for its Sofia 2 SARS Antigen+ FIA. The prescription test is well-suited to point-of-care settings, supporting companies’ efforts to expand their product offerings for infectious disease testing. This approval reflects the ongoing trend of companies looking at upgrading diagnostic offerings by securing regulatory approvals and launching more advanced tests to respond to growing demand.

North America Dominates Point-of-Care Diagnostics Market Share

North America holds the largest share in the point-of-care diagnostics market due to robust healthcare infrastructure and is largely supported by the government, which leads to the encouragement of innovation and significant adoption of more advanced diagnostic technologies. The presence of prominent market players creates competition, and this, in turn, leads to a continued development in product offerings. For instance, in July 2023, Vital Biosciences Inc., a Canada-based company, launched its first point-of-care testing platform, VitalOne, a compact device roughly the size of a desktop computer, at the Annual Meeting of the American Association of Clinical Chemistry. It will revolutionize diagnostics, as the system can provide more than 50 lab-grade results within 20 minutes. Moreover, regional companies are streamlining efforts, helping drive its leadership. In July 2024, Babson Diagnostics, Inc. introduced its new BetterWay blood testing service at Austin retail pharmacies. This BetterWay enables patients to be tested at retail pharmacies. This makes access easier for consumers. This will encourage more people to seek such diagnostic services, further fueling the demand in the market.

Download Free Sample Report

Future Market Scenario (2024-2031F)

This market is expected to hold several growth opportunities in the coming years due to an increasing prevalence of infectious disease, advancement in point-of-care diagnostic technologies, growing advancements in home care diagnostics, and an increase in investments toward research and development activities. In addition, AI-integrated testing holds great promise in the future toward both accuracy and usability, and researchers are working to make the innovation even better. For example, in August 2024, a team at the University of California, Los Angeles (UCLA) managed to design an AI-based test similar to home-based COVID-19 tests that would detect Lyme disease accurately in under 20 minutes.

Report Scope

“Point-of-Care Diagnostics Market Assessment, Opportunities and Forecast, 2017-2031F”, is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of the global point-of-care diagnostics market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecast between 2024 and 2031. Additionally, the report profiles the leading players in the industry, mentioning their respective market share, business models, competitive intelligence, etc.

Click here for full report- https://www.marketsandata.com/industry-reports/point-of-care-diagnostics-market

Latest reports-

Contact

Mr. Vivek Gupta 5741 Cleveland street, Suite 120, VA beach, VA, USA 23462 Tel: +1 (757) 343–3258 Email: info@marketsandata.com Website: https://www.marketsandata.com

[health-views-updates]

Radiopharmaceuticals Market Size, Share, and Revenue Forecast for 2024-2032

The global Radiopharmaceuticals Market Revenue is projected to achieve significant growth over the forecast period, driven by advancements in nuclear medicine and an increasing prevalence of chronic diseases. According to the latest report by SNS Insider, the market is experiencing strong momentum due to the growing adoption of radiopharmaceuticals in oncology, cardiology, and neurology. The report provides an in-depth analysis of market dynamics, key trends, and future opportunities that are shaping the industry.

Radiopharmaceuticals, known for their unique ability to deliver targeted radiation therapy and imaging, have become a cornerstone in modern medicine. The market has witnessed substantial investment in research and development, leading to innovations that enhance diagnostic precision and therapeutic outcomes. As regulatory frameworks evolve and become more favorable, the accessibility of radiopharmaceuticals in emerging markets is also improving, creating new avenues for market growth.

The surge in cancer cases globally has particularly underscored the importance of radiopharmaceuticals. With advancements in imaging technologies such as PET and SPECT, coupled with the integration of artificial intelligence in diagnostics, the role of radiopharmaceuticals is expected to expand further, offering enhanced patient care and reducing healthcare costs.

Get Free Sample Report: Click Here

Key Market Drivers and Opportunities

Rising Prevalence of Chronic Diseases: The growing burden of cancer and cardiovascular diseases has led to increased utilization of radiopharmaceuticals for accurate diagnosis and effective treatment.

Technological Advancements: Innovations in nuclear imaging and therapeutic radiopharmaceuticals are driving market expansion, enabling precise targeting of diseased tissues while minimizing side effects.

Supportive Government Policies: Increased funding and favorable regulations for nuclear medicine research are boosting the development and adoption of radiopharmaceuticals across regions.

Expansion in Emerging Markets: Rapid improvements in healthcare infrastructure in developing economies are creating significant growth opportunities for the industry.

Regional Insights

North America continues to dominate the radiopharmaceuticals market, driven by advanced healthcare infrastructure, a high prevalence of chronic diseases, and ongoing R&D activities. Europe is also witnessing robust growth due to increasing investments in nuclear medicine. Meanwhile, Asia-Pacific is emerging as a lucrative region owing to rising healthcare expenditure, growing awareness, and a large patient population.

Competitive Landscape

The report highlights key players in the radiopharmaceuticals market, including GE Healthcare, Cardinal Health, Lantheus Holdings, and Bayer AG. These companies are focused on strategic partnerships, mergers, and acquisitions to strengthen their market position. The development of next-generation radiopharmaceuticals and personalized medicine is also a significant focus area for industry leaders.

Future Outlook

The radiopharmaceuticals market is poised for transformative growth as advancements in nuclear medicine continue to revolutionize diagnostic and therapeutic applications. The integration of AI and big data analytics is expected to further enhance the precision and efficiency of radiopharmaceuticals, paving the way for improved patient outcomes and streamlined healthcare processes.

About Us

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Contact Us: Akash Anand – Head of Business Development & Strategy Email: info@snsinsider.com Phone: +1-415-230-0044 (US) | +91-7798602273 (IND)

[farmacuticals]

The Impact of Advanced Imaging Technologies on the Medical Camera Market

The medical camera market has been growing rapidly, driven by advancements in healthcare technology and an increasing need for high-quality imaging solutions in medical practices. Medical cameras are essential tools in modern healthcare, as they enable precise diagnosis, support minimally invasive surgeries, and enhance patient outcomes by providing clear visuals for medical professionals. These devices range from small, handheld cameras for quick diagnostics to sophisticated surgical and endoscopic cameras used in complex procedures. They are employed across various specialties, including dermatology, dentistry, ophthalmology, and oncology, where accurate visuals are critical.

The Medical Camera Market Size was projected to reach 4.93 billion USD in 2022, according to MRFR analysis. By 2032, the medical camera market is projected to have grown from 5.37 billion USD in 2023 to 11.64 billion USD. During the forecast period (2024-2032), the medical camera market's compound annual growth rate (CAGR) is anticipated to be approximately 8.97%.

Medical Camera Market Size

The medical camera market size has seen a substantial increase over recent years due to rising healthcare expenditure and growing demand for advanced diagnostic and imaging techniques. The aging population, especially in regions like North America and Europe, has contributed to the demand for better healthcare infrastructure, including the adoption of advanced imaging tools. Additionally, the surge in chronic diseases such as cancer and cardiovascular issues has further accelerated the adoption of medical cameras. As of the latest estimates, the market is projected to continue growing, with a compound annual growth rate (CAGR) that reflects the strong demand from healthcare institutions and technological innovations from leading manufacturers.

Medical Camera Market Share

The medical camera market share is primarily held by major players, including prominent technology companies and specialized medical device manufacturers. North America holds a significant portion of the global market share, attributed to the region's advanced healthcare facilities and the presence of key market players. However, Asia-Pacific is emerging as a significant contributor, driven by increased healthcare investment, growing medical tourism, and rising awareness of advanced diagnostic tools in countries like China, India, and Japan. Europe also holds a strong market share, supported by its robust healthcare policies and adoption of new medical technologies.

Medical Camera Market Analysis

Medical camera market analysis reveals several key factors contributing to its expansion. One of the primary drivers is the shift towards minimally invasive surgeries, which require high-quality imaging to enable precise and effective treatment with minimal recovery time. The demand for endoscopic and surgical cameras has risen as these tools aid in reducing surgical complications and improving patient outcomes. The increasing emphasis on telemedicine and remote monitoring has also spurred demand for diagnostic cameras that can capture and transmit images in real-time. However, the market faces challenges, including the high cost of advanced medical cameras and stringent regulatory policies, which may limit access to certain products in low-income regions.

Medical Camera Market Trends

The medical camera market trends highlight a growing focus on technological advancements such as 4K and 3D imaging, which enhance the clarity and depth of visuals. AI-powered imaging solutions are also becoming popular, helping healthcare professionals analyze images more accurately and efficiently. Additionally, there is a rising demand for wireless and portable cameras, which provide flexibility and ease of use in various medical settings. With these innovations, the medical camera market is anticipated to attract more healthcare facilities aiming to improve diagnostic accuracy and patient care.

Reasons to Buy the Report

Comprehensive Insights: The report provides a detailed analysis of the medical camera market size, share, trends, and forecasts, offering valuable insights for stakeholders.

Competitive Landscape: It offers a breakdown of the competitive landscape, including profiles of key players and their strategies to help businesses understand their position in the market.

Technological Advancements: Gain knowledge on the latest technological developments, such as AI, 4K imaging, and portable devices, shaping the future of medical imaging.

Investment Opportunities: The report highlights potential areas for investment in the medical camera market, valuable for investors seeking high-growth opportunities.

Market Drivers and Challenges: Detailed information on factors driving market growth and potential challenges, assisting businesses in strategic decision-making.

Recent Developments in the Medical Camera Market

Recent developments in the medical camera market include the introduction of advanced AI-based diagnostic cameras that enhance image accuracy, making it easier for medical professionals to detect abnormalities. Additionally, several companies are investing in ultra-high-definition 4K cameras, which offer unparalleled visual clarity, essential for complex surgeries. The trend toward miniaturized, portable devices has also gained momentum, especially for applications in remote healthcare and emergency medicine. Furthermore, the growing adoption of 3D imaging has improved depth perception in surgical procedures, which is critical for accuracy and precision. These advancements reflect the dynamic nature of the medical camera market and its response to evolving healthcare needs.

Relate reports:

antacid market

artificial intelligence in pharmaceutical market

artificial intelligence medical diagnostics market

Top of Form

Bottom of Form

[mordormr]

The Active Pharmaceutical Ingredients (API) Industry: Driving Growth and Innovation in Pharmaceuticals

The Active Pharmaceutical Ingredients (API) Market Size is projected to be valued at USD 216.5 billion in 2024, with expectations to grow to USD 306.90 billion by 2029, reflecting a CAGR of 7.22% over the forecast period (2024-2029).

Market Overview and Growth Factors

The global API market is experiencing robust expansion, driven by the rising prevalence of chronic and lifestyle-related diseases, advancements in biopharmaceuticals, and growing generic drug production. The demand for high-quality, affordable drugs is fueling the need for APIs, especially as healthcare accessibility improves worldwide. Additionally, the surge in demand for innovative drugs and targeted therapies, particularly for diseases like cancer, diabetes, and cardiovascular disorders, is propelling the API sector forward.

Key Trends in the API Market

Growing Demand for Specialty APIs Specialty APIs, such as high-potency active pharmaceutical ingredients (HPAPIs) and biologics, are seeing heightened demand due to their effectiveness in treating complex diseases. HPAPIs, particularly, are gaining traction in oncology treatments due to their targeted approach, which minimizes adverse effects and improves patient outcomes.

Focus on Quality and Compliance Regulatory standards for API manufacturing are becoming increasingly stringent, with a focus on Good Manufacturing Practices (GMP). This emphasis on compliance ensures product quality and safety, essential for patient health. Global regulatory bodies, such as the FDA and EMA, are imposing rigorous oversight, and compliance is now a competitive differentiator in the API industry.

Rise in Biotech and Biopharmaceuticals Biotechnology-based APIs are gaining ground in treating previously unmanageable conditions. Biologics, biosimilars, and vaccines are increasingly contributing to API demand. As biopharmaceutical R&D investments increase, the demand for biologic APIs is expected to climb, fueling industry growth.

API Manufacturing Outsourcing Many pharmaceutical companies are outsourcing API production to focus on core competencies. This trend reduces operational costs and taps into specialized expertise in regions like Asia-Pacific, where API manufacturing is more cost-effective and has well-established supply chains.

Innovation in Drug Manufacturing Processes Advanced technologies such as continuous manufacturing, green chemistry, and AI-driven optimization are reshaping the API landscape. These innovations enhance production efficiency, reduce costs, and minimize environmental impact, making API manufacturing more sustainable.

Conclusion

The Active Pharmaceutical Ingredients (API) industry is set for sustained growth, supported by rising healthcare needs, regulatory advancements, and innovations in drug manufacturing. As APIs remain integral to drug formulation and therapeutic efficacy, this market is crucial to advancements in global healthcare. Strategic outsourcing, enhanced quality standards, and technological progress in API production are likely to remain key drivers in the sector's development. In a dynamic pharmaceutical landscape, the API industry is well-positioned to support the demand for high-quality, effective medications that enhance patient outcomes worldwide.

For a detailed overview and more insights, you can refer to the full market research report by Mordor Intelligence https://www.mordorintelligence.com/industry-reports/global-active-pharmaceutical-ingredients-api-market  

[jayanthitbrc]

Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Analysis 2024: Size Forecast and Growth Prospects

The c-x-c chemokine receptor 4 (cxcr4) antagonists global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.

C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.

Market Size - The C-X-C chemokine receptor 4 (CXCR4) antagonist market size has grown strongly in recent years. It will grow from $1.49 billion in 2023 to $1.62 billion in 2024 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to increasing transparency in clinical trial data, patient-centric healthcare policies, rising prevalence of chemotherapy resistance, policies emphasizing patient-centered care and access, and increasing preference for targeted therapies.

The C-X-C chemokine receptor 4 (CXCR4) antagonist market size is expected to see strong growth in the next few years. It will grow to $2.33 billion in 2028 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to expanding applications in HIV or AIDS, rising demand for stem cell mobilization, potential in autoimmune diseases, growth in biobanking initiatives, and integration of artificial intelligence (AI) in drug discovery. Major trends in the forecast period include increasing focus on orphan drug development, development of combination therapies, adoption of precision oncology approaches, expanding clinical trials for novel therapies, and advancements in drug delivery technologies.

Order your report now for swift delivery @ https://www.thebusinessresearchcompany.com/report/c-x-c-chemokine-receptor-4-cxcr4-antagonists-global-market-report

Scope Of C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market The Business Research Company's reports encompass a wide range of information, including:

1. Market Size (Historic and Forecast): Analysis of the market's historical performance and projections for future growth.

2. Drivers: Examination of the key factors propelling market growth.

3. Trends: Identification of emerging trends and patterns shaping the market landscape.

4. Key Segments: Breakdown of the market into its primary segments and their respective performance.

5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.

6. Macro Economic Factors: Assessment of broader economic elements impacting the market.

C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Overview

Market Drivers - The increase in the prevalence of human immunodeficiency virus (HIV) is expected to propel the growth of the spasmodic dysphonia treatment market going forward. Human immunodeficiency virus (HIV) is a virus that targets and weakens the immune system by attacking CD4 (T) cells, potentially leading to AIDS if left untreated. HIV prevalence is rising due to low awareness, limited healthcare access, higher transmission rates, and inadequate prevention in some areas. CXCR4 antagonists block the CXCR4 receptor, stopping HIV from accessing and infecting immune cells, which aids in controlling the virus and enhancing the immune response. For instance, according to Joint United Nations Programme on HIV/AIDS (UNAIDS), in 2022, there were 39 million [33.1 million-45.7 million] HIV-positive people worldwide, with 1.3 million [1 million-1.7 million] people newly infected with HIV in 2022. Therefore, the increase in the prevalence of human immunodeficiency virus (HIV) is driving the growth of the CXCR4 antagonist market.

Market Trends - Major companies operating in the CXCR4 antagonist market are focusing on developing bioequivalents to enhance treatment options and improve patient outcomes in various diseases. Bioequivalent refers to pharmaceutical products with similar bioavailability when compared under similar conditions. For instance, in May 2024, Gland Pharma, an India-based generic injectable manufacturing company, received approval from the United States Food and Drug Administration (US FDA) for Plerixafor Injection. The approved product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), MOZOBIL (plerixafor) injection of Genzyme Corporation. Plerixafor is a CXCR4 antagonist that, when used with granulocyte-colony stimulating factor, helps to mobilize hematopoietic stem cells into the peripheral blood for collection and autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.

The C-X-C chemokine receptor 4 (CXCR4) antagonists market covered in this report is segmented –

1) By Type: BL-8040, GMI-1359, Plerixafor (AMD3100), Balixafortide (POL6326), USL311, Burixafor (GPC-100), Other Types 2) By Route Of Administration: Oral, Injectable 3) By Product Pipeline: Approved, Clinical Trials, Pre-Clinical 4) By Application: Cancer, Human Immunodeficiency Virus (HIV), Chronic Inflammatory Disease, Stem Cell Mobilization, Immune And Autoimmune Diseases 5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Get an inside scoop of the c-x-c chemokine receptor 4 (cxcr4) antagonists market, Request now for Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=18329&type=smp

Regional Insights - North America was the largest region in the C-X-C chemokine receptor type 4 antagonists market in 2023. The regions covered in the C-X-C chemokine receptor 4 (CXCR4) antagonists market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Key Companies - Major companies operating in the C-X-C chemokine receptor 4 (CXCR4) antagonists market are Pfizer Inc., F-Hoffmann La Roche Ltd., Sanofi, Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline, Eli Lilly and Company, Amgen Inc., Takeda Chemical Industries Ltd., Kyowa Kirin Co. Ltd., BioLegend Inc., Kura Oncology Inc., CUSABIO TECHNOLOGY LLC, Cayman Chemical, X4 Pharmaceuticals Inc., BioLineRx Ltd., Spexis Ltd., Biokine Therapeutics Ltd., GlycoMimetics, AnorMED Inc., CohBar Inc.

Table of Contents 1. Executive Summary 2. C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Report Structure 3. C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Trends And Strategies 4. C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market – Macro Economic Scenario 5. C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Size And Growth ….. 27. C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Competitor Landscape And Company Profiles 28. Key Mergers And Acquisitions 29. Future Outlook and Potential Analysis 30. Appendix

Contact Us: The Business Research Company Europe: +44 207 1930 708 Asia: +91 88972 63534 Americas: +1 315 623 0293 Email: info@tbrc.info

Follow Us On: LinkedIn: https://in.linkedin.com/company/the-business-research-company Twitter: https://twitter.com/tbrc_info Facebook: https://www.facebook.com/TheBusinessResearchCompany YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ Blog: https://blog.tbrc.info/ Healthcare Blog: https://healthcareresearchreports.com/ Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

[market-insider]

Exploring the Clinical Trial Management Services Market: Detailed Insights on Size, Share, and Growth Potential

The global clinical trial management services market size is anticipated to reach USD 53.85 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 8.25% from 2024 to 2030. The increasing trend of outsourcing clinical trial activities, the rise in research and development of advanced therapies, and the globalization of clinical trials are a few key factors driving the growth of the market.

The number of clinical trials has significantly increased in the past two decades. This is due to the rising need for novel pharmaceutical products with improved efficacy as well as the increasing penetration of cutting-edge medical technologies. According to Clinical trials.gov, the total number of clinical trials accounted for 325,773 in 2020, whereas, as of April 2022, the number of clinical trials this year totaled more than 410,903.

Clinical Trial Management Services Market Report Highlights

The clinical trial monitoring segment dominated the market with a revenue share of 27.64% in 2023. The rising number of clinical trials and technological advancements in trial monitoring are key factors driving the growth.

The oncology segment dominated the market with a revenue share of 37.05% in 2023 and is expected to grow at the fastest CAGR of 8.45% during the forecast period.

The pharmaceuticals segment dominated the market with a revenue share of 38.96% in 2023. This can be largely attributed to the rise in R&D investments and the development of new drugs over the past two decades.

North America clinical trial management services market dominated globally in 2023 with the largest revenue share of 34.96%. The demand for new therapies and drugs has led to a surge in clinical trials across the region.

Asia Pacific clinical trial management services market is expected to grow at the fastest CAGR over the forecast period.

For More Details or Sample Copy please visit link @: Clinical Trial Management Services Market Report

Clinical trial management services such as clinical monitoring, data management, site monitoring, and medical writing service are cost-effective and time-saving. These also harmonize clinical data across sites and failure rates. Furthermore, the integration of digital technologies, including cloud computing, Artificial Intelligence (AI), big data prescriptive, and predictive analytics, the Internet of Medical Things, and mobile technology remain major developments on the horizon. These technologies have shown great promise in improving productivity while accelerating the pace of clinical trials.

The COVID-19 pandemic significantly impacted the market. It created an unexpected urgency for alternative solutions to clinical trial execution, limiting on-site monitoring visits. It prompted researchers to use remote clinical trial monitoring services and platforms to reduce the spread of the COVID-19 infection as well as to simultaneously function in clinical research. For instance, according to the Florence survey in 2020, more than 60% of clinical study sites and clinical trial sponsors stated more than 50% acceptance of remote site monitoring solutions for clinical research.

List of major companies in the Clinical Trial Management Services Market

CTI Clinical Trial & Consulting

Charles River Laboratories

Medpace Holdings, Inc.

Wuxi Apptec

SGS Société Générale de Surveillance SA

Laboratory Corporation of America Holdings

IQVIA, Inc.

Syneous Health

For Customized reports or Special Pricing please visit @: Clinical Trial Management Services Market Analysis Report

We have segmented global clinical trial management services market report based on services, indication, end-use, and region.

[trendingreportz]

Genomics Market - Forecast(2024 - 2030)

Global Genomic Market Overview:

A genome is the genetic material of an organism. It includes both the genes and the noncoding DNA, as well as mitochondrial DNA and chloroplast DNA. The study of genomes is called genomics. The genomics market is gaining traction owing to its applications in various fields of study such as intragenomic phenomenon including epistasis, pleiotropy, heterosis, and other interactions between loci and alleles within the genome. In this era of medical and life science innovations shaping itself as an inevitable uptake for sustainability of mankind, the genomic research is poised for exponential growth owing to imperative genetic innovations feeding off it. Abundant potential has driven this arcade to reach a staggering market size of $16 billion - $16.5 billion as of 2018, and the demand is estimated to increment at formidable CAGR of 9.2% to 10.2% during the forecast period of 2019 to 2025.

Request Sample

Global Genomic Market Outlook:

Genomics is extensively employed in healthcare, agriculture, biotechnology, DNA sequencing, and diagnostics. In the healthcare segment, genomics is used for the development of vaccines and drugs. This segment leads the application vertical and is growing with a CAGR of 10.1%-10.7 % through to 2025. Genomics plays a significant part in diagnosis of several genetic disorders. It has an ample scope in personalized medication as it can advocate a medical management constructed on the genetic face of a person with the help of clinical data and AI.  It is also applied in synthetic biology and bioengineering. Genomics research in agriculture is hired for plant breeding and genetics to cultivate crop production. The understanding of gene function and the accessibility of genomic maps along with an enhanced understanding of genetic variant will aid the plant breeders to identify the traits and then manipulate those traits to obtain a high yield. All these factors affecting the enormous medical and agricultural sector are all set to stroke the genomics market with abundant demand.

Inquiry Before Buying

Global Genomic Market Growth Drivers:

As per the National Center for Biotechnology Information, U.S, the progression in oncology (study and treatment of tumor) expenses is forecast to rise 7%–10% annually throughout 2020, with universal oncology cost exceeding $150 billion[1]. As per the WHO, cancer is a leading cause of death worldwide, accounting for an estimated 9.6 million deaths in 2018[2]. And the total annual economic cost of cancer at the initial period of this decade was estimated at approximately $1.16 trillion. Thus the application of genomics in exploring cell-free circulating DNA by several R&D sectors as a potential biomarker for cancers is driving the market towards exponential growth. The genomics market with its current potential displays all the necessary traits it can adapt in the coming years to divert a huge chunk of traffic and revenue from the omnipresent cancer diagnostics.

As per the Food and Agriculture Organization of United Nations, between 1960 and 1990 the arable land increased by 1.5 billion ha, and in the recent past decades the elevation recorded is just 155 million ha[3]. With decreasing arable floor and the increasing global population augmenting the demand for food by 70% (by 2050), obtaining a high yield is a major trend in the agricultural sector. Genomics market is all set to capitalize on this unprecedented demand scenario. Genomics supplements the understanding of gene function and the accessibility of genomic maps along with an enhanced understanding of genetic variant, thus aiding the plant breeders to identify the traits and then manipulate those traits to obtain a high yield.

After an acute analysis of the regional insights of the global genomics market, North America is revealed to hold 39% to 40% of the entire global market size as of 2018. Such dominance can be attributed to several aspects such as cumulative investment on research by federal administrations, growing patient awareness, and accessibility of urbane healthcare facilities.

Schedule a Call

Global Genomics Market Players Perspective:

Some of other key players profiled in this IndustryARC business intelligence report are Beckton Dickson, Synthetic Genomics Inc. (SGI) ,Cepheid, Inc., Affymetrix, Inc., Bio-Rad Laboratories, Inc., Agilent Technologies, GE Healthcare, Illumina, Inc., Danaher Corporation,F. Hoffmann-La Roche, QIAGEN, Thermo Fisher Scientific and PacBio (Pacific Biosciences of California). Majority of the companies mentioned are situated in North America augmenting the regional affluence in the global market.

Global Genomics Market Trends:

High overload owing to a wide range of reagents and consumables has propelled companies into approving different policies to endure in the market and stay ahead of the curve.

For instance, in January 2017, BD launched Precise WTA Reagents for precise and guileless quantification of hereditary data form single cell analysis. Moreover, in July 2016, SGI-DNA entered into a distribution agreement with VWR International, an American company involved in the distribution of research laboratory products, with over 1,200,000 items to more than 250,000 customers in North America and Europe.

Genomics Market Research Scope

The base year of the study is 2018, with forecast done up to 2025. The study presents a thorough analysis of the competitive landscape, taking into account the market shares of the leading companies. It also provides information on unit shipments. These provide the key market participants with the necessary business intelligence and help them understand the future of the Genomics Market. The assessment includes the forecast, an overview of the competitive structure, the market shares of the competitors, as well as the market trends, market demands, market drivers, market challenges, and product analysis. The market drivers and restraints have been assessed to fathom their impact over the forecast period. This report further identifies the key opportunities for growth while also detailing the key challenges and possible threats. The key areas of focus include the types of equipment in the Genomics Market, and their specific applications in different phases of industrial operations.

Buy Now

Genomics Market Report: Industry Coverage

Types of Solutions Genomics Market:

By Product Types- Microarray chip, Sequencers.

By Application- Genotyping, SNP analysis.

By End-User- Anthropology, Diagnostics.

The Genomics Market report also analyzes the major geographic regions for the market as well as the major countries for the market in these regions. The regions and countries covered in the study include:

North America: The U.S., Canada, Mexico

South America: Brazil, Venezuela, Argentina, Ecuador, Peru, Colombia, Costa Rica

Europe: The U.K., Germany, Italy, France, The Netherlands, Belgium, Spain, Denmark

APAC: China, Japan, Australia, South Korea, India, Taiwan, Malaysia, Hong Kong

Middle East and Africa: Israel, South Africa, Saudi Arabia

[insightfulblogz]

Blood Screening Market: Poor Demand in Underdeveloped Countries, 2032

Blood screening is a critical process in modern healthcare, ensuring the safety of blood transfusions and the early detection of diseases. This essential procedure involves testing donated blood for infectious agents, genetic markers, and other abnormalities to safeguard recipients and improve health outcomes. Advanced technologies, including automated systems and molecular diagnostics, have enhanced the speed, accuracy, and reliability of blood screening, cementing its role as a cornerstone of preventive medicine.

The Blood Screening Market size was estimated at USD 3.03 billion in 2023 and is expected to reach USD 6.98 billion by 2032 at a CAGR of 9.73% during the forecast period of 2024-2032.

Future Scope

The future of blood screening lies in the integration of next-generation sequencing (NGS) and AI-driven analytics. These technologies promise to identify rare pathogens and genetic mutations with unprecedented precision. Portable and point-of-care blood screening devices are also on the horizon, enabling faster diagnostics in remote or resource-limited settings. Additionally, advancements in biosensors and lab-on-a-chip technology are expected to revolutionize how blood screening is conducted, making it more accessible and efficient.

Emerging Trends

A notable trend in blood screening is the use of multiplex assays, which allow simultaneous detection of multiple pathogens in a single test. The rise of personalized medicine is driving the development of screening tools tailored to individual genetic profiles. Furthermore, blockchain technology is being explored to enhance data security and traceability in blood donation and testing processes. Innovations in automated sample processing and high-throughput screening systems are also reshaping the landscape.

Applications

Blood screening is vital in transfusion medicine, preventing the spread of infectious diseases like HIV, hepatitis, and syphilis. It plays a significant role in prenatal testing, helping detect genetic disorders in unborn babies. In oncology, blood screening is used for biomarker detection and monitoring cancer progression. Additionally, it aids in diagnosing chronic conditions such as diabetes and cardiovascular diseases, supporting effective disease management.

Key Points

Blood screening ensures safe transfusions and early disease detection.

Emerging technologies like NGS and AI are revolutionizing the process.

Multiplex assays enable the detection of multiple pathogens simultaneously.

Applications include transfusion safety, prenatal testing, and chronic disease management.

Biosensors and portable devices enhance accessibility and efficiency.

Conclusion

Blood screening remains an indispensable component of healthcare, safeguarding lives and supporting preventive medicine. With technological advancements driving greater accuracy and accessibility, the future of blood screening holds immense promise. As it evolves, blood screening will continue to play a pivotal role in improving global health outcomes, ensuring safety, and fostering trust in medical procedures.

Read More Details: https://www.snsinsider.com/reports/blood-screening-market-3151 

Contact Us:

Akash Anand — Head of Business Development & Strategy

Email: info@snsinsider.com

Phone: +1–415–230–0044 (US) | +91–7798602273 (IND) 

[communicationblogs]

Genomics Market — Forecast(2024–2030)

Genomics Market was worth US$ 30.84 Bn. in 2023 and total revenue is expected to grow at a rate of 15.35% CAGR from 2024 to 2030, reaching almost US$ 83.81 Bn. in 2030.

A genome is the genetic material of an organism. It includes both the genes and the noncoding DNA, as well as mitochondrial DNA and chloroplast DNA. The study of genomes is called genomics. The genomics market is gaining traction owing to its applications in various fields of study such as intragenomic phenomenon including epistasis, pleiotropy, heterosis, and other interactions between loci and alleles within the genome. In this era of medical and life science innovations shaping itself as an inevitable uptake for sustainability of mankind, the genomic research is poised for exponential growth owing to imperative genetic innovations feeding off it.

Request Sample

Global Genomic Market Outlook :

Genomics is extensively employed in healthcare, agriculture, biotechnology, DNA sequencing, and diagnostics. In the healthcare segment, genomics is used for the development of vaccines and drugs. This segment leads the application vertical and is growing with a CAGR of 10.1%-10.7 % through to 2025. Genomics plays a significant part in diagnosis of several genetic disorders. It has an ample scope in personalized medication as it can advocate a medical management constructed on the genetic face of a person with the help of clinical data and AI. It is also applied in synthetic biology and bioengineering. Genomics research in agriculture is hired for plant breeding and genetics to cultivate crop production. The understanding of gene function and the accessibility of genomic maps along with an enhanced understanding of genetic variant will aid the plant breeders to identify the traits and then manipulate those traits to obtain a high yield. All these factors affecting the enormous medical and agricultural sector are all set to stroke the genomics market with abundant demand.

Inquiry Before Buying

Global Genomic Market Growth Drivers:

As per the National Center for Biotechnology Information, U.S, the progression in oncology (study and treatment of tumor) expenses is forecast to rise 7%–10% annually throughout 2020, with universal oncology cost exceeding $150 billion[1]. As per the WHO, cancer is a leading cause of death worldwide, accounting for an estimated 9.6 million deaths in 2018[2]. And the total annual economic cost of cancer at the initial period of this decade was estimated at approximately $1.16 trillion. Thus the application of genomics in exploring cell-free circulating DNA by several R&D sectors as a potential biomarker for cancers is driving the market towards exponential growth. The genomics market with its current potential displays all the necessary traits it can adapt in the coming years to divert a huge chunk of traffic and revenue from the omnipresent cancer diagnostics.

Buy Now

As per the Food and Agriculture Organization of United Nations, between 1960 and 1990 the arable land increased by 1.5 billion ha, and in the recent past decades the elevation recorded is just 155 million ha[3]. With decreasing arable floor and the increasing global population augmenting the demand for food by 70% (by 2050), obtaining a high yield is a major trend in the agricultural sector. Genomics market is all set to capitalize on this unprecedented demand scenario. Genomics supplements the understanding of gene function and the accessibility of genomic maps along with an enhanced understanding of genetic variant, thus aiding the plant breeders to identify the traits and then manipulate those traits to obtain a high yield.

After an acute analysis of the regional insights of the global genomics market, North America is revealed to hold 39% to 40% of the entire global market size as of 2018. Such dominance can be attributed to several aspects such as cumulative investment on research by federal administrations, growing patient awareness, and accessibility of urbane healthcare facilities.

About IndustryARC™: 

IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications of the Market. Our Custom Research Services are designed to provide insights on the constant flux in the global demand-supply gap of markets. Our strong analyst team enables us to meet the client research needs at a very quick speed with a variety of options for your business. We look forward to support the client to be able to better address customer needs; stay ahead in the market; become the top competitor and get real-time recommendations on business strategies and deals. 

Contact Us: https://tinyurl.com/4ddrycjw

Website URL: https://www.industryarc.com/